This event has ended. Visit the official site or create your own event on Sched.

View analytic
Monday, June 27 • 2:30pm - 4:00pm
#151: Plenary Session and Keynote Address

Sign up or log in to save this to your schedule and see who's attending!

Limited Capacity seats available

Component Type: Session
Level: Intermediate

Join us for the DIA 2016 Keynote Address.


Sandra A. Milligan, JD, MD


Welcome Remarks
Barbara Lopez Kunz, MSc

Welcome Remarks
Tatsuo Kurokawa, PhD

Opening Remarks
Hans-Georg Eichler

Opening Remarks
Gigi Hirsch, MD

Keynote Address: Bad Bugs, Good People, and Big, Bold Ideas
Larry Brilliant

avatar for Sandra Milligan

Sandra Milligan

Senior Vice President, Head of Regulatory Affairs and Safety, Merck Research Laboratories
Sandra Milligan, MD, JD, is Vice President, Global Regulatory, Immunology, Infectious Diseases and Ophthalmology for Genentech/Roche, developing and directing global strategic regulatory plans to facilitate and optimize product development, regulatory approval, and commercialization. Sandra is the President-Elect for the DIA Board of Directors.

avatar for Larry Brilliant

Larry Brilliant

Chairman, Skoll Global Threats Fund
avatar for Hans-Georg Eichler

Hans-Georg Eichler

Senior Medical Officer, European Medicines Agency, European Union
Dr. Eichler is responsible for coordinating activities between the European Medicine Agency's (EMA) scientific committees and giving advice on scientific and public health issues. Prior to joining EMA, Dr. Eichler was professor and chair of clinical pharmacology and vice-rector at the Medical University of Vienna. Other positions held include President of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of... Read More →
avatar for Gigi Hirsch

Gigi Hirsch

Executive Director, Massachusetts Institute of Technology (MIT) Center For Biomedical Innovation
Her current efforts are leading the New Drug Development Paradigms initiative (NEWDIGS), a “think and do tank” that is re-engineering pharmaceutical innovation to deliver new, better, affordable therapeutics to the right patients, faster. Within the broad strategic framework of “Adaptive Biomedical Innovation,” NEWDIGS’ flagship project focused on aligning stakeholders around more adaptive, patient-centered approaches to the... Read More →
avatar for Tatsuo Kurokawa

Tatsuo Kurokawa

President, Japan Self-Medication Industry
Dr. Tatsuo Kurokawa started his career as a staff of Japan’s Ministry of Health, Labour and Welfare (MHLW). It includes NDA review, pharmacovigilance and drug safety measures, WHO activities, ICH and international collaboration. After retirement from Government official, he became a professor of Drug Development and Regulatory Sciences, Faculty of Pharmacy, Keio University. He is a member of the DIA Board of Directors since 2009 and Chair of... Read More →

Monday June 27, 2016 2:30pm - 4:00pm
Ballroom AB Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA